DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Tazemetostat hydrobromideis the generic ingredient in one branded drug marketed by Epizyme Inc and is included in one NDA. There are twenty-three patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Tazemetostat hydrobromide has three hundred and four patent family members in thirty-eight countries.
Recent Clinical Trials for tazemetostat hydrobromide
Identify potential brand extensions & 505(b)(2) entrants
|National Cancer Institute (NCI)||Phase 1/Phase 2|
|Country||Patent Number||Estimated Expiration|
|Singapore||11201703806X||⤷ Free Forever Trial|
|Argentina||093244||⤷ Free Forever Trial|
|Singapore||10201903356X||⤷ Free Forever Trial|
|Spain||2570380||⤷ Free Forever Trial|
|Hungary||E028837||⤷ Free Forever Trial|
|Taiwan||201302704||⤷ Free Forever Trial|
|New Zealand||746054||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|